#  @MonteRosaTx Monte Rosa Therapeutics, Inc Monte Rosa Therapeutics, Inc posts on X about study, science, key, we are the most. They currently have [-----] followers and [--] posts still getting attention that total [--] engagements in the last [--] hours. ### Engagements: [--] [#](/creator/twitter::1260881559504269314/interactions)  - [--] Week [---] +74% - [--] Year [-----] +8.40% ### Mentions: [--] [#](/creator/twitter::1260881559504269314/posts_active)  - [--] Year [--] -63% ### Followers: [-----] [#](/creator/twitter::1260881559504269314/followers)  - [--] Week [-----] -0.08% - [--] Month [-----] +1.10% - [--] Year [-----] +16% ### CreatorRank: undefined [#](/creator/twitter::1260881559504269314/influencer_rank)  ### Social Influence **Social category influence** [stocks](/list/stocks) [finance](/list/finance) **Social topic influence** [study](/topic/study), [science](/topic/science), [key](/topic/key), [we are](/topic/we-are), [future](/topic/future), [for the](/topic/for-the), [execution](/topic/execution), [cancer](/topic/cancer), [glue](/topic/glue), [novartis](/topic/novartis) **Top accounts mentioned or mentioned by** [@roche](/creator/undefined) [@novartis](/creator/undefined) [@naturecommshttpstcozt9zho98gi](/creator/undefined) [@sciencemagazine](/creator/undefined) [@keystonesymp](/creator/undefined) [@trendsinbiotech](/creator/undefined) [@naturesmb](/creator/undefined) [@americanheart](/creator/undefined) [@sabcssanantonio](/creator/undefined) [@markuswarmuth](/creator/undefined) [@zavaindar](/creator/undefined) [@financebully](/creator/undefined) [@bioworld](/creator/undefined) [@biotechhealthx](/creator/undefined) **Top assets mentioned** [Novartis AG (NVS)](/topic/novartis) [Monte Rosa Therapeutics, Inc. (GLUE)](/topic/$glue) ### Top Social Posts Top posts by engagements in the last [--] hours "Congrats to the winner of the first ever Monte Rosa ping pong tournament You are the champion 🎶" [X Link](https://x.com/MonteRosaTx/status/1431277383689113602) 2021-08-27T15:28Z [----] followers, [--] engagements "Happy Birthday to the legendary Freddie Mercury Through our proprietary QuEEN platform (Yes The name of our QuEEN was inspired by THAT Queen) we aim to revolutionize the way we treat human diseases the way Freddie revolutionized modern day music" [X Link](https://x.com/MonteRosaTx/status/1699081244124811513) 2023-09-05T15:25Z [---] followers, [---] engagements "Today we are celebrating two milestones including interim data from our Phase 1/2 trial of MRT-2359. We believe the results the first ever to show clinical activity of a rationally designed #moleculargluedegrader in solid tumors represent an important advance for the field" [X Link](https://x.com/MonteRosaTx/status/1714239457707033035) 2023-10-17T11:18Z [----] followers, [--] engagements "We are also pleased to announce a strategic #collaboration with @Roche which enables and accelerates the expansion of our platform into neuroscience and additional areas of oncology. #biotech #innovation #drugdiscovery" [X Link](https://x.com/MonteRosaTx/status/1714239458881544692) 2023-10-17T11:18Z [---] followers, [---] engagements "We are honored to partner with @Roche. Their recognition of the potential in #moleculargluedegraders and expertise in developing and commercializing innovative therapies accelerate our mission to deliver transformative treatments to patients" [X Link](https://x.com/MonteRosaTx/status/1714656638571786515) 2023-10-18T14:56Z [---] followers, [----] engagements "How can artificial intelligence revolutionize biotechs approach to drug discovery Watch Part [--] of our video series Using AI to Rewrite MGD Discovery as our leadership discusses the crucial role of AI in our process & how teams work hand-in-hand: https://bit.ly/4dELhoc https://bit.ly/4dELhoc" [X Link](https://x.com/MonteRosaTx/status/1790403929353674970) 2024-05-14T15:28Z [---] followers, [----] engagements "Were presenting preclinical data at @SABCSSanAntonio on the potential of our highly selective cyclin-dependent kinase [--] (CDK2)-directed molecular glue degrader. Learn more: https://bit.ly/4f8gpvL https://bit.ly/4f8gpvL" [X Link](https://x.com/MonteRosaTx/status/1866832274190176296) 2024-12-11T13:07Z [----] followers, [----] engagements "Today we announced that our CEOMarkus Warmuth will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday January 14th at 5:15 p.m. PST.We look forward to seeing you all in San Francisco #JPM2025 https://bit.ly/41W5mTE https://bit.ly/41W5mTE" [X Link](https://x.com/MonteRosaTx/status/1876256700183032234) 2025-01-06T13:17Z [----] followers, [---] engagements "2024 was a year of breakthroughs and growth at Monte Rosa. We advanced clinical programs presented groundbreaking research forged a global license agreement with Novartis and celebrated leadership growth" [X Link](https://x.com/MonteRosaTx/status/1878790052198952977) 2025-01-13T13:03Z [----] followers, [---] engagements "Today we announced our second collaboration with @Novartis to develop novel degraders for immune-mediated diseases. Given the strong progress weve made on our collaboration advancing VAV1 degraders were thrilled to be collaborating with them again: https://bit.ly/4piSOyN https://bit.ly/4piSOyN" [X Link](https://x.com/MonteRosaTx/status/1967545913486065746) 2025-09-15T11:07Z [----] followers, [----] engagements "This weeks announcement of a second collaboration with @Novartis includes an exclusive license to an undisclosed discovery target and options to license two preclinical immunology programs. CEO @markus_warmuth comments: https://bit.ly/4piSOyN https://bit.ly/4piSOyN" [X Link](https://x.com/MonteRosaTx/status/1967922034908033533) 2025-09-16T12:02Z [----] followers, [---] engagements "We are presenting preclinical data at the 36th EORTC-NCI-AACR Symposium (ENA [----] #TripleMeeting) on the potential of our cyclin E1 (CCNE1)-targeted molecular glue degraders (MGDs) for the treatment of CCNE1-amplified solid tumors" [X Link](https://x.com/MonteRosaTx/status/1849059495508341208) 2024-10-23T12:05Z [----] followers, [---] engagements "Our CSO Sharon Townson comments on the preclinical data we presented at the #TripleMeeting [----] and on the potential of our Cyclin E1-targeted MGDs across various solid tumor types. https://bit.ly/48knMib https://bit.ly/48knMib" [X Link](https://x.com/MonteRosaTx/status/1849109552966271097) 2024-10-23T15:24Z [----] followers, [---] engagements "Data highlight: When dosed orally as a single agent in preclinical models of CCNE1-amplified breast cancer and gastric cancer the cyclin E1-directed MGD MRT-50969 induced robust tumor growth suppression and regression" [X Link](https://x.com/MonteRosaTx/status/1849109554325238270) 2024-10-23T15:24Z [----] followers, [---] engagements "Our CMO Filip Janku will participate in a virtual fireside chat at the TD Cowen Immunology & Inflammation Summit to discuss how we're advancing our I&I portfolio. Register or view the webcast: https://bit.ly/49doujF https://bit.ly/49doujF" [X Link](https://x.com/MonteRosaTx/status/1988958645963616716) 2025-11-13T13:14Z [----] followers, [---] engagements "Through proteomic profiling of our proprietary compound library our team identified a selective fast and potent molecular glue degrader that induces cereblon degradation via a novel mechanism. Read the full paper in https://rdcu.be/eQKQk https://rdcu.be/eQKQk" [X Link](https://x.com/anyuser/status/1991166702109802547) 2025-11-19T15:28Z [----] followers, [---] engagements "Our colleagues break down the work behind this years @ScienceMagazine cover story and what it means for the future of molecular glue degrader (MGD) development: https://bit.ly/4oHaJxy https://bit.ly/4oHaJxy" [X Link](https://x.com/anyuser/status/1998377409817854235) 2025-12-09T13:01Z [----] followers, [---] engagements "Today we announced promising interim results from an ongoing Phase 1/2 clinical study evaluating MRT-2359 in combination with enzalutamide in heavily pretreated patients with mCRPC. CEO Markus Warmuth shares his perspective on the data. https://bit.ly/4af3cCL https://bit.ly/4af3cCL" [X Link](https://x.com/anyuser/status/2000905922357457366) 2025-12-16T12:28Z [----] followers, [---] engagements "In [----] we made meaningful clinical progress deepened scientific leadership through key publications and expanded strategic collaborations. Looking ahead we are focused on rigorous science purposeful execution and delivering differentiated medicines for patients" [X Link](https://x.com/anyuser/status/2003090750775636300) 2025-12-22T13:10Z [----] followers, [---] engagements "ICYMI: In [----] we made meaningful clinical progress deepened scientific leadership through key publications and expanded strategic collaborations. Looking ahead we are focused on rigorous science purposeful execution and delivering differentiated medicines for patients" [X Link](https://x.com/anyuser/status/2008535947298959789) 2026-01-06T13:47Z [----] followers, [---] engagements "We present findings today at #KSAutoimmune26 highlighting VAV1s key role in T/B cell function and the broad therapeutic potential of MRT-6160 across multiple immune-mediated diseases including SLE Sjgrens disease rheumatoid arthritis IBD and others" [X Link](https://x.com/anyuser/status/2013961330789601469) 2026-01-21T13:06Z [----] followers, [---] engagements "ICYMI: Adam Cartwright presented findings at #KSAutoimmune26 on MRT-6160 in multiple immune-mediated disease models. Thanks to @KeystoneSymp for convening such a rich and engaging event. View the presentation here: https://bit.ly/3NMm02U https://bit.ly/3NMm02U" [X Link](https://x.com/anyuser/status/2015777766474457537) 2026-01-26T13:24Z [----] followers, [---] engagements "CEO Markus Warmuth shares his perspective on the future of Monte Rosa and molecular glue degraders in a fireside chat today at the Guggenheim 2nd Annual Healthcare Innovation Conference. To register: https://bit.ly/3JrSnCt https://bit.ly/3JrSnCt" [X Link](https://x.com/MonteRosaTx/status/1987867958073548810) 2025-11-10T13:00Z [----] followers, [---] engagements "ICYMI this year we were thrilled to be named Biotech of the Year at the 8th Annual #TPD and Induced Proximity Summit. Thanks to the organizers for setting up a great meeting and congratulations to our entire team" [X Link](https://x.com/anyuser/status/1990766829095342334) 2025-11-18T12:59Z [----] followers, [---] engagements "Tune in for a fireside chat with Markus Warmuth at the Piper Sandler 37th Annual Healthcare Conference where hell share insights on Monte Rosa and the progress of our molecular glue degraders. To register: https://bit.ly/3XqBvPM https://bit.ly/3XqBvPM" [X Link](https://x.com/anyuser/status/1995843066130014598) 2025-12-02T13:10Z [----] followers, [---] engagements "Our invited review in @TrendsinBiotech is now out in print. The piece explores how machine learning can predict de novo proteinprotein interactions including those induced by our molecular glues. Kudos to the team for their leadership in this field: https://bit.ly/3Y503xT https://bit.ly/3Y503xT" [X Link](https://x.com/anyuser/status/1996252967809204528) 2025-12-03T16:19Z [----] followers, [----] engagements "We will host a conference call and live webcast at 8am ET on Tuesday Dec [--] to provide interim clinical results from the ongoing Phase 1/2 study of MRT-2359 in heavily pretreated metastatic castration-resistant prostate cancer patients. To access: https://bit.ly/3KSVjbQ https://bit.ly/3KSVjbQ" [X Link](https://x.com/anyuser/status/2000681140105974182) 2025-12-15T21:35Z [----] followers, [---] engagements "This holiday season our team came together to support our communities in meaningful ways. Volunteering side by side not only allows us to give back - it strengthens our collaboration and sense of purpose long after the day of service ends" [X Link](https://x.com/anyuser/status/2001638395261653343) 2025-12-18T12:59Z [----] followers, [---] engagements "Conference call and webcast presentation today January [--] [----] at 8:00 a.m. ET. A webcast of the presentation will be accessible via the Events & Presentations section of Monte Rosas website. https://bit.ly/3LeETuB https://bit.ly/3LeETuB" [X Link](https://x.com/anyuser/status/2008874339320692923) 2026-01-07T12:12Z [----] followers, [---] engagements "Today we reported positive interim data from an ongoing Phase [--] study of MRT-8102. We believe these data support the potential of MRT-8102 to be an oral best-in-class therapeutic among agents targeting the NRLP3/IL-1/IL-6 pathway. https://bit.ly/4pxGtWz https://bit.ly/4pxGtWz" [X Link](https://x.com/anyuser/status/2008938208848167204) 2026-01-07T16:26Z [----] followers, [---] engagements "CMO Filip Janku comments on the future clinical plans for MRT-8102 based on the highly encouraging data we have observed so far in our ongoing Phase [--] study. Read the full data release here: https://bit.ly/4pxGtWz https://bit.ly/4pxGtWz" [X Link](https://x.com/anyuser/status/2010732086752419932) 2026-01-12T15:14Z [----] followers, [---] engagements "New findings in @NatureSMB challenge the current understanding of how neosubstrates bind cereblon. We show G3BP2 bypasses canonical rules of CRBN engagement & introduce glueprints as a new way to potentially expand the MGD target space: https://go.nature.com/4qzdbIr https://go.nature.com/4qzdbIr" [X Link](https://x.com/anyuser/status/2013600360737222958) 2026-01-20T13:11Z [----] followers, [---] engagements "On #WorldCancerDay were proud to stand #UnitedByUnique. At Monte Rosa our paths into oncology may differ but were united in pushing drug discovery forward with the goal to develop precision treatments for people living with cancer. Learn more: https://bit.ly/3ZQqqIO https://bit.ly/3ZQqqIO" [X Link](https://x.com/anyuser/status/2019033920952770794) 2026-02-04T13:02Z [----] followers, [---] engagements "ASCVD affects 40M+ people in the U.S. and is the leading cause of death worldwide yet many are unfamiliar with it. Caused by plaque buildup in the arteries it can lead to heart attack and stroke. This Heart Health Month learn more from @American_Heart: https://bit.ly/3LCK8o7 https://bit.ly/3LCK8o7" [X Link](https://x.com/anyuser/status/2020845621402534139) 2026-02-09T13:01Z [----] followers, [---] engagements "Today we announced positive interim data from an ongoing Phase [--] clinical study evaluating MRT-8102 a NEK7-directed MGD being developed for the treatment of inflammatory conditions driven by the NLRP3 inflammasome IL-1 and IL-6" [X Link](https://x.com/anyuser/status/2008874337718407448) 2026-01-07T12:12Z [----] followers, [----] engagements "On International Day of Women and Girls in Science were celebrating the individuals advancing scientific innovation. From Boston to Basel women at Monte Rosa are turning insight into impact for patients and the next generation. Learn more: #February11 https://bit.ly/3Oiaz3e https://bit.ly/3Oiaz3e" [X Link](https://x.com/anyuser/status/2021570614704607525) 2026-02-11T13:02Z [----] followers, [---] engagements "On International Day of Women and Girls in Science were celebrating the individuals advancing scientific innovation. From Boston to Basel women at Monte Rosa are turning insight into impact for patients and the next generation. Learn more: #February11 https://bit.ly/3Oiaz3e https://bit.ly/3Oiaz3e" [X Link](https://x.com/anyuser/status/2021570614704607525) 2026-02-11T13:02Z [----] followers, [---] engagements "ASCVD affects 40M+ people in the U.S. and is the leading cause of death worldwide yet many are unfamiliar with it. Caused by plaque buildup in the arteries it can lead to heart attack and stroke. This Heart Health Month learn more from @American_Heart: https://bit.ly/3LCK8o7 https://bit.ly/3LCK8o7" [X Link](https://x.com/anyuser/status/2020845621402534139) 2026-02-09T13:01Z [----] followers, [---] engagements "On #WorldCancerDay were proud to stand #UnitedByUnique. At Monte Rosa our paths into oncology may differ but were united in pushing drug discovery forward with the goal to develop precision treatments for people living with cancer. Learn more: https://bit.ly/3ZQqqIO https://bit.ly/3ZQqqIO" [X Link](https://x.com/anyuser/status/2019033920952770794) 2026-02-04T13:02Z [----] followers, [---] engagements "ICYMI: Adam Cartwright presented findings at #KSAutoimmune26 on MRT-6160 in multiple immune-mediated disease models. Thanks to @KeystoneSymp for convening such a rich and engaging event. View the presentation here: https://bit.ly/3NMm02U https://bit.ly/3NMm02U" [X Link](https://x.com/anyuser/status/2015777766474457537) 2026-01-26T13:24Z [----] followers, [---] engagements "We present findings today at #KSAutoimmune26 highlighting VAV1s key role in T/B cell function and the broad therapeutic potential of MRT-6160 across multiple immune-mediated diseases including SLE Sjgrens disease rheumatoid arthritis IBD and others" [X Link](https://x.com/anyuser/status/2013961330789601469) 2026-01-21T13:06Z [----] followers, [---] engagements "New findings in @NatureSMB challenge the current understanding of how neosubstrates bind cereblon. We show G3BP2 bypasses canonical rules of CRBN engagement & introduce glueprints as a new way to potentially expand the MGD target space: https://go.nature.com/4qzdbIr https://go.nature.com/4qzdbIr" [X Link](https://x.com/anyuser/status/2013600360737222958) 2026-01-20T13:11Z [----] followers, [---] engagements "CMO Filip Janku comments on the future clinical plans for MRT-8102 based on the highly encouraging data we have observed so far in our ongoing Phase [--] study. Read the full data release here: https://bit.ly/4pxGtWz https://bit.ly/4pxGtWz" [X Link](https://x.com/anyuser/status/2010732086752419932) 2026-01-12T15:14Z [----] followers, [---] engagements "Today we reported positive interim data from an ongoing Phase [--] study of MRT-8102. We believe these data support the potential of MRT-8102 to be an oral best-in-class therapeutic among agents targeting the NRLP3/IL-1/IL-6 pathway. https://bit.ly/4pxGtWz https://bit.ly/4pxGtWz" [X Link](https://x.com/anyuser/status/2008938208848167204) 2026-01-07T16:26Z [----] followers, [---] engagements "Today we announced positive interim data from an ongoing Phase [--] clinical study evaluating MRT-8102 a NEK7-directed MGD being developed for the treatment of inflammatory conditions driven by the NLRP3 inflammasome IL-1 and IL-6" [X Link](https://x.com/anyuser/status/2008874337718407448) 2026-01-07T12:12Z [----] followers, [----] engagements "Conference call and webcast presentation today January [--] [----] at 8:00 a.m. ET. A webcast of the presentation will be accessible via the Events & Presentations section of Monte Rosas website. https://bit.ly/3LeETuB https://bit.ly/3LeETuB" [X Link](https://x.com/anyuser/status/2008874339320692923) 2026-01-07T12:12Z [----] followers, [---] engagements "ICYMI: In [----] we made meaningful clinical progress deepened scientific leadership through key publications and expanded strategic collaborations. Looking ahead we are focused on rigorous science purposeful execution and delivering differentiated medicines for patients" [X Link](https://x.com/anyuser/status/2008535947298959789) 2026-01-06T13:47Z [----] followers, [---] engagements "In [----] we made meaningful clinical progress deepened scientific leadership through key publications and expanded strategic collaborations. Looking ahead we are focused on rigorous science purposeful execution and delivering differentiated medicines for patients" [X Link](https://x.com/anyuser/status/2003090750775636300) 2025-12-22T13:10Z [----] followers, [---] engagements "This holiday season our team came together to support our communities in meaningful ways. Volunteering side by side not only allows us to give back - it strengthens our collaboration and sense of purpose long after the day of service ends" [X Link](https://x.com/anyuser/status/2001638395261653343) 2025-12-18T12:59Z [----] followers, [---] engagements "Today we announced promising interim results from an ongoing Phase 1/2 clinical study evaluating MRT-2359 in combination with enzalutamide in heavily pretreated patients with mCRPC. CEO Markus Warmuth shares his perspective on the data. https://bit.ly/4af3cCL https://bit.ly/4af3cCL" [X Link](https://x.com/anyuser/status/2000905922357457366) 2025-12-16T12:28Z [----] followers, [---] engagements "We will host a conference call and live webcast at 8am ET on Tuesday Dec [--] to provide interim clinical results from the ongoing Phase 1/2 study of MRT-2359 in heavily pretreated metastatic castration-resistant prostate cancer patients. To access: https://bit.ly/3KSVjbQ https://bit.ly/3KSVjbQ" [X Link](https://x.com/anyuser/status/2000681140105974182) 2025-12-15T21:35Z [----] followers, [---] engagements "Our colleagues break down the work behind this years @ScienceMagazine cover story and what it means for the future of molecular glue degrader (MGD) development: https://bit.ly/4oHaJxy https://bit.ly/4oHaJxy" [X Link](https://x.com/anyuser/status/1998377409817854235) 2025-12-09T13:01Z [----] followers, [---] engagements "Our invited review in @TrendsinBiotech is now out in print. The piece explores how machine learning can predict de novo proteinprotein interactions including those induced by our molecular glues. Kudos to the team for their leadership in this field: https://bit.ly/3Y503xT https://bit.ly/3Y503xT" [X Link](https://x.com/anyuser/status/1996252967809204528) 2025-12-03T16:19Z [----] followers, [----] engagements "Tune in for a fireside chat with Markus Warmuth at the Piper Sandler 37th Annual Healthcare Conference where hell share insights on Monte Rosa and the progress of our molecular glue degraders. To register: https://bit.ly/3XqBvPM https://bit.ly/3XqBvPM" [X Link](https://x.com/anyuser/status/1995843066130014598) 2025-12-02T13:10Z [----] followers, [---] engagements "Through proteomic profiling of our proprietary compound library our team identified a selective fast and potent molecular glue degrader that induces cereblon degradation via a novel mechanism. Read the full paper in https://rdcu.be/eQKQk https://rdcu.be/eQKQk" [X Link](https://x.com/anyuser/status/1991166702109802547) 2025-11-19T15:28Z [----] followers, [---] engagements "ICYMI this year we were thrilled to be named Biotech of the Year at the 8th Annual #TPD and Induced Proximity Summit. Thanks to the organizers for setting up a great meeting and congratulations to our entire team" [X Link](https://x.com/anyuser/status/1990766829095342334) 2025-11-18T12:59Z [----] followers, [---] engagements Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing
@MonteRosaTx Monte Rosa Therapeutics, Inc
Monte Rosa Therapeutics, Inc posts on X about study, science, key, we are the most. They currently have [-----] followers and [--] posts still getting attention that total [--] engagements in the last [--] hours.
Engagements: [--] #
- [--] Week [---] +74%
- [--] Year [-----] +8.40%
Mentions: [--] #
- [--] Year [--] -63%
Followers: [-----] #
- [--] Week [-----] -0.08%
- [--] Month [-----] +1.10%
- [--] Year [-----] +16%
CreatorRank: undefined #
Social Influence
Social category influence stocks finance
Social topic influence study, science, key, we are, future, for the, execution, cancer, glue, novartis
Top accounts mentioned or mentioned by @roche @novartis @naturecommshttpstcozt9zho98gi @sciencemagazine @keystonesymp @trendsinbiotech @naturesmb @americanheart @sabcssanantonio @markuswarmuth @zavaindar @financebully @bioworld @biotechhealthx
Top assets mentioned Novartis AG (NVS) Monte Rosa Therapeutics, Inc. (GLUE)
Top Social Posts
Top posts by engagements in the last [--] hours
"Congrats to the winner of the first ever Monte Rosa ping pong tournament You are the champion 🎶"
X Link 2021-08-27T15:28Z [----] followers, [--] engagements
"Happy Birthday to the legendary Freddie Mercury Through our proprietary QuEEN platform (Yes The name of our QuEEN was inspired by THAT Queen) we aim to revolutionize the way we treat human diseases the way Freddie revolutionized modern day music"
X Link 2023-09-05T15:25Z [---] followers, [---] engagements
"Today we are celebrating two milestones including interim data from our Phase 1/2 trial of MRT-2359. We believe the results the first ever to show clinical activity of a rationally designed #moleculargluedegrader in solid tumors represent an important advance for the field"
X Link 2023-10-17T11:18Z [----] followers, [--] engagements
"We are also pleased to announce a strategic #collaboration with @Roche which enables and accelerates the expansion of our platform into neuroscience and additional areas of oncology. #biotech #innovation #drugdiscovery"
X Link 2023-10-17T11:18Z [---] followers, [---] engagements
"We are honored to partner with @Roche. Their recognition of the potential in #moleculargluedegraders and expertise in developing and commercializing innovative therapies accelerate our mission to deliver transformative treatments to patients"
X Link 2023-10-18T14:56Z [---] followers, [----] engagements
"How can artificial intelligence revolutionize biotechs approach to drug discovery Watch Part [--] of our video series Using AI to Rewrite MGD Discovery as our leadership discusses the crucial role of AI in our process & how teams work hand-in-hand: https://bit.ly/4dELhoc https://bit.ly/4dELhoc"
X Link 2024-05-14T15:28Z [---] followers, [----] engagements
"Were presenting preclinical data at @SABCSSanAntonio on the potential of our highly selective cyclin-dependent kinase [--] (CDK2)-directed molecular glue degrader. Learn more: https://bit.ly/4f8gpvL https://bit.ly/4f8gpvL"
X Link 2024-12-11T13:07Z [----] followers, [----] engagements
"Today we announced that our CEOMarkus Warmuth will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday January 14th at 5:15 p.m. PST.We look forward to seeing you all in San Francisco #JPM2025 https://bit.ly/41W5mTE https://bit.ly/41W5mTE"
X Link 2025-01-06T13:17Z [----] followers, [---] engagements
"2024 was a year of breakthroughs and growth at Monte Rosa. We advanced clinical programs presented groundbreaking research forged a global license agreement with Novartis and celebrated leadership growth"
X Link 2025-01-13T13:03Z [----] followers, [---] engagements
"Today we announced our second collaboration with @Novartis to develop novel degraders for immune-mediated diseases. Given the strong progress weve made on our collaboration advancing VAV1 degraders were thrilled to be collaborating with them again: https://bit.ly/4piSOyN https://bit.ly/4piSOyN"
X Link 2025-09-15T11:07Z [----] followers, [----] engagements
"This weeks announcement of a second collaboration with @Novartis includes an exclusive license to an undisclosed discovery target and options to license two preclinical immunology programs. CEO @markus_warmuth comments: https://bit.ly/4piSOyN https://bit.ly/4piSOyN"
X Link 2025-09-16T12:02Z [----] followers, [---] engagements
"We are presenting preclinical data at the 36th EORTC-NCI-AACR Symposium (ENA [----] #TripleMeeting) on the potential of our cyclin E1 (CCNE1)-targeted molecular glue degraders (MGDs) for the treatment of CCNE1-amplified solid tumors"
X Link 2024-10-23T12:05Z [----] followers, [---] engagements
"Our CSO Sharon Townson comments on the preclinical data we presented at the #TripleMeeting [----] and on the potential of our Cyclin E1-targeted MGDs across various solid tumor types. https://bit.ly/48knMib https://bit.ly/48knMib"
X Link 2024-10-23T15:24Z [----] followers, [---] engagements
"Data highlight: When dosed orally as a single agent in preclinical models of CCNE1-amplified breast cancer and gastric cancer the cyclin E1-directed MGD MRT-50969 induced robust tumor growth suppression and regression"
X Link 2024-10-23T15:24Z [----] followers, [---] engagements
"Our CMO Filip Janku will participate in a virtual fireside chat at the TD Cowen Immunology & Inflammation Summit to discuss how we're advancing our I&I portfolio. Register or view the webcast: https://bit.ly/49doujF https://bit.ly/49doujF"
X Link 2025-11-13T13:14Z [----] followers, [---] engagements
"Through proteomic profiling of our proprietary compound library our team identified a selective fast and potent molecular glue degrader that induces cereblon degradation via a novel mechanism. Read the full paper in https://rdcu.be/eQKQk https://rdcu.be/eQKQk"
X Link 2025-11-19T15:28Z [----] followers, [---] engagements
"Our colleagues break down the work behind this years @ScienceMagazine cover story and what it means for the future of molecular glue degrader (MGD) development: https://bit.ly/4oHaJxy https://bit.ly/4oHaJxy"
X Link 2025-12-09T13:01Z [----] followers, [---] engagements
"Today we announced promising interim results from an ongoing Phase 1/2 clinical study evaluating MRT-2359 in combination with enzalutamide in heavily pretreated patients with mCRPC. CEO Markus Warmuth shares his perspective on the data. https://bit.ly/4af3cCL https://bit.ly/4af3cCL"
X Link 2025-12-16T12:28Z [----] followers, [---] engagements
"In [----] we made meaningful clinical progress deepened scientific leadership through key publications and expanded strategic collaborations. Looking ahead we are focused on rigorous science purposeful execution and delivering differentiated medicines for patients"
X Link 2025-12-22T13:10Z [----] followers, [---] engagements
"ICYMI: In [----] we made meaningful clinical progress deepened scientific leadership through key publications and expanded strategic collaborations. Looking ahead we are focused on rigorous science purposeful execution and delivering differentiated medicines for patients"
X Link 2026-01-06T13:47Z [----] followers, [---] engagements
"We present findings today at #KSAutoimmune26 highlighting VAV1s key role in T/B cell function and the broad therapeutic potential of MRT-6160 across multiple immune-mediated diseases including SLE Sjgrens disease rheumatoid arthritis IBD and others"
X Link 2026-01-21T13:06Z [----] followers, [---] engagements
"ICYMI: Adam Cartwright presented findings at #KSAutoimmune26 on MRT-6160 in multiple immune-mediated disease models. Thanks to @KeystoneSymp for convening such a rich and engaging event. View the presentation here: https://bit.ly/3NMm02U https://bit.ly/3NMm02U"
X Link 2026-01-26T13:24Z [----] followers, [---] engagements
"CEO Markus Warmuth shares his perspective on the future of Monte Rosa and molecular glue degraders in a fireside chat today at the Guggenheim 2nd Annual Healthcare Innovation Conference. To register: https://bit.ly/3JrSnCt https://bit.ly/3JrSnCt"
X Link 2025-11-10T13:00Z [----] followers, [---] engagements
"ICYMI this year we were thrilled to be named Biotech of the Year at the 8th Annual #TPD and Induced Proximity Summit. Thanks to the organizers for setting up a great meeting and congratulations to our entire team"
X Link 2025-11-18T12:59Z [----] followers, [---] engagements
"Tune in for a fireside chat with Markus Warmuth at the Piper Sandler 37th Annual Healthcare Conference where hell share insights on Monte Rosa and the progress of our molecular glue degraders. To register: https://bit.ly/3XqBvPM https://bit.ly/3XqBvPM"
X Link 2025-12-02T13:10Z [----] followers, [---] engagements
"Our invited review in @TrendsinBiotech is now out in print. The piece explores how machine learning can predict de novo proteinprotein interactions including those induced by our molecular glues. Kudos to the team for their leadership in this field: https://bit.ly/3Y503xT https://bit.ly/3Y503xT"
X Link 2025-12-03T16:19Z [----] followers, [----] engagements
"We will host a conference call and live webcast at 8am ET on Tuesday Dec [--] to provide interim clinical results from the ongoing Phase 1/2 study of MRT-2359 in heavily pretreated metastatic castration-resistant prostate cancer patients. To access: https://bit.ly/3KSVjbQ https://bit.ly/3KSVjbQ"
X Link 2025-12-15T21:35Z [----] followers, [---] engagements
"This holiday season our team came together to support our communities in meaningful ways. Volunteering side by side not only allows us to give back - it strengthens our collaboration and sense of purpose long after the day of service ends"
X Link 2025-12-18T12:59Z [----] followers, [---] engagements
"Conference call and webcast presentation today January [--] [----] at 8:00 a.m. ET. A webcast of the presentation will be accessible via the Events & Presentations section of Monte Rosas website. https://bit.ly/3LeETuB https://bit.ly/3LeETuB"
X Link 2026-01-07T12:12Z [----] followers, [---] engagements
"Today we reported positive interim data from an ongoing Phase [--] study of MRT-8102. We believe these data support the potential of MRT-8102 to be an oral best-in-class therapeutic among agents targeting the NRLP3/IL-1/IL-6 pathway. https://bit.ly/4pxGtWz https://bit.ly/4pxGtWz"
X Link 2026-01-07T16:26Z [----] followers, [---] engagements
"CMO Filip Janku comments on the future clinical plans for MRT-8102 based on the highly encouraging data we have observed so far in our ongoing Phase [--] study. Read the full data release here: https://bit.ly/4pxGtWz https://bit.ly/4pxGtWz"
X Link 2026-01-12T15:14Z [----] followers, [---] engagements
"New findings in @NatureSMB challenge the current understanding of how neosubstrates bind cereblon. We show G3BP2 bypasses canonical rules of CRBN engagement & introduce glueprints as a new way to potentially expand the MGD target space: https://go.nature.com/4qzdbIr https://go.nature.com/4qzdbIr"
X Link 2026-01-20T13:11Z [----] followers, [---] engagements
"On #WorldCancerDay were proud to stand #UnitedByUnique. At Monte Rosa our paths into oncology may differ but were united in pushing drug discovery forward with the goal to develop precision treatments for people living with cancer. Learn more: https://bit.ly/3ZQqqIO https://bit.ly/3ZQqqIO"
X Link 2026-02-04T13:02Z [----] followers, [---] engagements
"ASCVD affects 40M+ people in the U.S. and is the leading cause of death worldwide yet many are unfamiliar with it. Caused by plaque buildup in the arteries it can lead to heart attack and stroke. This Heart Health Month learn more from @American_Heart: https://bit.ly/3LCK8o7 https://bit.ly/3LCK8o7"
X Link 2026-02-09T13:01Z [----] followers, [---] engagements
"Today we announced positive interim data from an ongoing Phase [--] clinical study evaluating MRT-8102 a NEK7-directed MGD being developed for the treatment of inflammatory conditions driven by the NLRP3 inflammasome IL-1 and IL-6"
X Link 2026-01-07T12:12Z [----] followers, [----] engagements
"On International Day of Women and Girls in Science were celebrating the individuals advancing scientific innovation. From Boston to Basel women at Monte Rosa are turning insight into impact for patients and the next generation. Learn more: #February11 https://bit.ly/3Oiaz3e https://bit.ly/3Oiaz3e"
X Link 2026-02-11T13:02Z [----] followers, [---] engagements
"On International Day of Women and Girls in Science were celebrating the individuals advancing scientific innovation. From Boston to Basel women at Monte Rosa are turning insight into impact for patients and the next generation. Learn more: #February11 https://bit.ly/3Oiaz3e https://bit.ly/3Oiaz3e"
X Link 2026-02-11T13:02Z [----] followers, [---] engagements
"ASCVD affects 40M+ people in the U.S. and is the leading cause of death worldwide yet many are unfamiliar with it. Caused by plaque buildup in the arteries it can lead to heart attack and stroke. This Heart Health Month learn more from @American_Heart: https://bit.ly/3LCK8o7 https://bit.ly/3LCK8o7"
X Link 2026-02-09T13:01Z [----] followers, [---] engagements
"On #WorldCancerDay were proud to stand #UnitedByUnique. At Monte Rosa our paths into oncology may differ but were united in pushing drug discovery forward with the goal to develop precision treatments for people living with cancer. Learn more: https://bit.ly/3ZQqqIO https://bit.ly/3ZQqqIO"
X Link 2026-02-04T13:02Z [----] followers, [---] engagements
"ICYMI: Adam Cartwright presented findings at #KSAutoimmune26 on MRT-6160 in multiple immune-mediated disease models. Thanks to @KeystoneSymp for convening such a rich and engaging event. View the presentation here: https://bit.ly/3NMm02U https://bit.ly/3NMm02U"
X Link 2026-01-26T13:24Z [----] followers, [---] engagements
"We present findings today at #KSAutoimmune26 highlighting VAV1s key role in T/B cell function and the broad therapeutic potential of MRT-6160 across multiple immune-mediated diseases including SLE Sjgrens disease rheumatoid arthritis IBD and others"
X Link 2026-01-21T13:06Z [----] followers, [---] engagements
"New findings in @NatureSMB challenge the current understanding of how neosubstrates bind cereblon. We show G3BP2 bypasses canonical rules of CRBN engagement & introduce glueprints as a new way to potentially expand the MGD target space: https://go.nature.com/4qzdbIr https://go.nature.com/4qzdbIr"
X Link 2026-01-20T13:11Z [----] followers, [---] engagements
"CMO Filip Janku comments on the future clinical plans for MRT-8102 based on the highly encouraging data we have observed so far in our ongoing Phase [--] study. Read the full data release here: https://bit.ly/4pxGtWz https://bit.ly/4pxGtWz"
X Link 2026-01-12T15:14Z [----] followers, [---] engagements
"Today we reported positive interim data from an ongoing Phase [--] study of MRT-8102. We believe these data support the potential of MRT-8102 to be an oral best-in-class therapeutic among agents targeting the NRLP3/IL-1/IL-6 pathway. https://bit.ly/4pxGtWz https://bit.ly/4pxGtWz"
X Link 2026-01-07T16:26Z [----] followers, [---] engagements
"Today we announced positive interim data from an ongoing Phase [--] clinical study evaluating MRT-8102 a NEK7-directed MGD being developed for the treatment of inflammatory conditions driven by the NLRP3 inflammasome IL-1 and IL-6"
X Link 2026-01-07T12:12Z [----] followers, [----] engagements
"Conference call and webcast presentation today January [--] [----] at 8:00 a.m. ET. A webcast of the presentation will be accessible via the Events & Presentations section of Monte Rosas website. https://bit.ly/3LeETuB https://bit.ly/3LeETuB"
X Link 2026-01-07T12:12Z [----] followers, [---] engagements
"ICYMI: In [----] we made meaningful clinical progress deepened scientific leadership through key publications and expanded strategic collaborations. Looking ahead we are focused on rigorous science purposeful execution and delivering differentiated medicines for patients"
X Link 2026-01-06T13:47Z [----] followers, [---] engagements
"In [----] we made meaningful clinical progress deepened scientific leadership through key publications and expanded strategic collaborations. Looking ahead we are focused on rigorous science purposeful execution and delivering differentiated medicines for patients"
X Link 2025-12-22T13:10Z [----] followers, [---] engagements
"This holiday season our team came together to support our communities in meaningful ways. Volunteering side by side not only allows us to give back - it strengthens our collaboration and sense of purpose long after the day of service ends"
X Link 2025-12-18T12:59Z [----] followers, [---] engagements
"Today we announced promising interim results from an ongoing Phase 1/2 clinical study evaluating MRT-2359 in combination with enzalutamide in heavily pretreated patients with mCRPC. CEO Markus Warmuth shares his perspective on the data. https://bit.ly/4af3cCL https://bit.ly/4af3cCL"
X Link 2025-12-16T12:28Z [----] followers, [---] engagements
"We will host a conference call and live webcast at 8am ET on Tuesday Dec [--] to provide interim clinical results from the ongoing Phase 1/2 study of MRT-2359 in heavily pretreated metastatic castration-resistant prostate cancer patients. To access: https://bit.ly/3KSVjbQ https://bit.ly/3KSVjbQ"
X Link 2025-12-15T21:35Z [----] followers, [---] engagements
"Our colleagues break down the work behind this years @ScienceMagazine cover story and what it means for the future of molecular glue degrader (MGD) development: https://bit.ly/4oHaJxy https://bit.ly/4oHaJxy"
X Link 2025-12-09T13:01Z [----] followers, [---] engagements
"Our invited review in @TrendsinBiotech is now out in print. The piece explores how machine learning can predict de novo proteinprotein interactions including those induced by our molecular glues. Kudos to the team for their leadership in this field: https://bit.ly/3Y503xT https://bit.ly/3Y503xT"
X Link 2025-12-03T16:19Z [----] followers, [----] engagements
"Tune in for a fireside chat with Markus Warmuth at the Piper Sandler 37th Annual Healthcare Conference where hell share insights on Monte Rosa and the progress of our molecular glue degraders. To register: https://bit.ly/3XqBvPM https://bit.ly/3XqBvPM"
X Link 2025-12-02T13:10Z [----] followers, [---] engagements
"Through proteomic profiling of our proprietary compound library our team identified a selective fast and potent molecular glue degrader that induces cereblon degradation via a novel mechanism. Read the full paper in https://rdcu.be/eQKQk https://rdcu.be/eQKQk"
X Link 2025-11-19T15:28Z [----] followers, [---] engagements
"ICYMI this year we were thrilled to be named Biotech of the Year at the 8th Annual #TPD and Induced Proximity Summit. Thanks to the organizers for setting up a great meeting and congratulations to our entire team"
X Link 2025-11-18T12:59Z [----] followers, [---] engagements
Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing